Rapid and efficient protocols to generate oligodendrocytes (OL) from human induced
pluripotent stem cells (iPSC) are currently lacking, but may be a key technology to …

Scarce access to primary samples and lack of efficient protocols to generate
oligodendrocytes (OLs) from human pluripotent stem cells (hPSCs) are hampering our …

In the CNS, oligodendrocytes act as the myelinating cells. Oligodendrocytes have been
identified to be key players in several neurodegenerative disorders. This protocol describes …

Oligodendrocytes (OLs) are responsible for myelin production and metabolic support of
neurons. Defects in OLs are crucial in several neurodegenerative diseases including …

Transplantation of oligodendrocyte precursor cells (OPCs) is a promising potential
therapeutic strategy for diseases affecting myelin. However, the derivation of engraftable …

Multiple sclerosis (MS) is a chronic demyelinating disease of unknown etiology that affects
the CNS. While current therapies are primarily directed against the immune system, the new …

Myelin-related disorders such as multiple sclerosis and leukodystrophies, for which
restoration of oligodendrocyte function would be an effective treatment, are poised to benefit …

We have developed a four-part protocol to differentiate human embryonic stem cells
(hESCs) to oligodendrocyte progenitor cells (OPCs) according to developmental principles …

The technology to generate autologous pluripotent stem cells (iPS cells) from almost any
somatic cell type has brought various cell replacement therapies within clinical research …

Oligodendroglial pathology is central to de‐and dysmyelinating, but also contributes to
neurodegenerative and psychiatric diseases as well as brain injury. The understanding of …